PPB (Kenya)

PPB (Pharmacy and Poisons Board) is Kenya's national regulatory authority responsible for regulating the practice of pharmacy + the manufacture + trade in drugs + poisons + medical devices + health technologies in Kenya. PPB was established in 1957 under the Pharmacy and Poisons Act (Cap 244 of the Laws of Kenya), which has been substantially amended through subsequent statutes including the Pharmacy and Poisons (Amendment) Act 2002 + the Health Act 21 of 2017. PPB's headquarters is in Nairobi at Lenana Road + the agency operates Regional Offices across Kenya's 47 counties + Port-of-Entry offices at Mombasa seaport + Jomo Kenyatta International Airport + Eldoret + Kisumu airports + land borders (Namanga with Tanzania, Busia + Malaba with Uganda, Moyale with Ethiopia).

PPB's organisational structure includes:

• Chief Executive Officer / Registrar — chief executive appointed by the Board + accountable to the Cabinet Secretary for Health; serves a fixed term renewable.
• Board of the Pharmacy and Poisons Board — chaired by a Ministerial appointee + including the Registrar + representatives of the Pharmaceutical Society of Kenya + Kenya Medical Association + Ministry of Health + Council of Legal Education + civil society.
• Directorate of Pharmacovigilance, Clinical Trials + Cosmetovigilance — operates the National Pharmacovigilance Centre + Med Safety App + clinical-trial oversight + cosmetovigilance.
• Directorate of Product Evaluation + Registration — drug + biological + biosimilar + vaccine + herbal-medicine + medical-device + IVD + cosmetic registration.
• Directorate of Inspection + Surveillance — GMP / GDP / GCP inspection of Kenyan + foreign facilities + ports-of-entry + post-market surveillance.
• Directorate of Pharmacy Practice + Premises Licensing — pharmacist registration + pharmacy premises licensing + pharmacy ethics + discipline (a function that sits inside PPB in Kenya, distinguishing PPB from peer NRAs).
• Directorate of Substance Use Disorders + Controlled Substances — controlled-substance scheduling + Schedule I-V controls + Single Convention compliance.
• National Quality Control Laboratory (NQCL) — Kenya's national pharmaceutical quality-control laboratory located at Kenyatta National Hospital; WHO-prequalified for quality control + serves PPB + WHO PQ + Global Fund + Gavi procurement.
• Directorate of Legal Affairs + Enforcement — counterfeit-medicine enforcement under the Anti-Counterfeit Act + cooperation with the Anti-Counterfeit Authority (ACA) + Kenya Bureau of Standards (KEBS).
• Directorate of Corporate Services — finance, ICT, HR + administration.
• Directorate of Communication + Public Affairs — consumer education + risk communication + media relations.

PPB's hybrid product-regulator + professional-regulator role distinguishes it from peer NRAs. In Kenya, PPB regulates BOTH pharmaceutical products (registration, GMP, pharmacovigilance) AND pharmacy practice (pharmacist registration, pharmacy premises licensing) — whereas in Nigeria the Pharmacists Council of Nigeria (PCN) handles practice + NAFDAC handles products; in Ghana the Pharmacy Council handles practice + Ghana FDA handles products; in South Africa the South African Pharmacy Council handles practice + SAHPRA handles products. This consolidated model is shared with several other EAC NRAs including Tanzania TMDA + Uganda NDA + Rwanda FDA.

PPB is distinct from + complementary to: the Pharmaceutical Society of Kenya (PSK, a professional body advocating for pharmacists); the Kenya Medical Practitioners and Dentists Council (KMPDC, which regulates medical + dental practice); the Kenya Health Professions Oversight Authority (KHPOA, which coordinates health-profession councils); the Kenya Medical Research Institute (KEMRI, which conducts health research + collaborates on clinical trials); the Anti-Counterfeit Authority (ACA, which leads counterfeit-product enforcement across all sectors); the Kenya Bureau of Standards (KEBS, which sets non-health-related industrial standards); + the Directorate of Veterinary Services (DVS, which regulates veterinary practice — though veterinary medicines are jointly regulated by PPB + DVS).

Legal foundations are the Pharmacy and Poisons Act (Cap 244), the Health Act 21 of 2017, the PPB Guidelines on Submission of Documentation for Registration of Pharmaceutical Products, the PPB Good Manufacturing Practice Guidelines, the PPB Medical Devices and IVDs Guidelines + a substantial body of PPB technical guidelines.

PPB is pursuing WHO Maturity Level 3 (ML3) under the WHO Global Benchmarking Tool framework + has indicated intention to achieve ML3 for vaccines + medicines as a near-term milestone. PPB has applied for PIC/S Membership + is an active participant in WHO PQ CRP, EAC-MRH, AMRH + ICDRA.

Kenyan pharmaceutical regulation operates under a layered framework of primary legislation + PPB guidelines:

• Pharmacy and Poisons Act (Cap 244 of the Laws of Kenya, 1957 as amended) — primary legislation establishing PPB + its functions, powers + governance; provides for Board appointment + Registrar.
• Health Act 21 of 2017 — overarching health-sector legislation including pharmaceutical-product framework + pharmacovigilance + cosmetovigilance + medical-device framework.
• Anti-Counterfeit Act 13 of 2008 — anti-counterfeit framework administered by the Anti-Counterfeit Authority (ACA) with PPB cooperation on counterfeit-medicine enforcement.
• PPB Guidelines on Submission of Documentation for Registration of Pharmaceutical Products — current registration framework for medicines + biologicals + biosimilars + vaccines.
• PPB Guidelines for Registration of Herbal + Complementary Medicinal Products — herbal medicines + nutraceuticals framework.
• PPB Good Manufacturing Practice Guidelines — current Kenyan GMP guidelines substantively aligned with WHO TRS 986 Annex 2 + ICH Q7 + EU GMP; mandatory for Kenyan + foreign manufacturers exporting to Kenya.
• PPB Good Clinical Practice Guidelines — substantively aligned with ICH E6(R2) GCP; mandatory for clinical trials conducted in Kenya.
• PPB Good Distribution Practice Guidelines — substantively aligned with WHO + EU GDP.
• PPB Pharmacovigilance Guidelines + National Pharmacovigilance System Strategic Plan — substantively aligned with WHO + EU GVP Modules; Kenya operates the Med Safety App + Yellow Form + ADR reporting.
• PPB Medical Devices and IVDs Guidelines — risk-based Class A-D framework substantively aligned with GHTF/IMDRF + EU MDR + ISO 13485 with Kenyan-specific overlay.
• PPB Cosmetics Guidelines + Cosmetovigilance Guidelines — registration + labelling + safety substantiation for cosmetics + cosmetovigilance reporting.
• PPB Variations Guidelines — Type IA / IB / II variations procedure substantively similar to WHO + EU + EAC-MRH variations framework.
• PPB Promotion and Advertisement of Medicines Guidelines — pre-approval of medicines + medical-device advertising + promotional materials.
• PPB Pharmacy Premises Licensing Guidelines — pharmacy premises licensing + practice standards (a function unique to consolidated NRAs like PPB).

Kenya's National Quality Control Laboratory (NQCL) is a centrally important asset of PPB + Kenya's pharmaceutical regulatory infrastructure. Located at Kenyatta National Hospital in Nairobi, NQCL is WHO-prequalified for pharmaceutical quality control + serves both PPB + WHO Prequalification + Global Fund + Gavi + USAID procurement programmes.

• WHO-Prequalified Laboratory (PQ-Lab) — NQCL achieved WHO Prequalification of Quality Control Laboratories status + maintains it through periodic WHO inspections; only a handful of African PQ-Labs exist (NQCL Kenya + NCQAL Tanzania + LANSPEX Cameroon + LNCQM Burkina Faso + a few others).
• PPB regulatory laboratory — NQCL conducts pre-registration quality testing + post-market surveillance testing + lot-release testing on behalf of PPB; results are direct PPB regulatory evidence.
• WHO PQ contract laboratory — NQCL conducts independent quality testing for WHO PQ programmes including HIV / TB / malaria / reproductive-health / maternal-child-health medicines.
• Global Fund + Gavi + USAID contract laboratory — NQCL conducts independent quality testing for Global Fund + Gavi + USAID procurement programmes serving Kenya + the East African Community + broader Africa.
• ISO/IEC 17025-accredited — NQCL is ISO/IEC 17025-accredited by KENAS (Kenya Accreditation Service) for pharmaceutical chemical + microbiological + biological testing.
• Regional reference role — NQCL provides quality-control testing services for EAC Partner States that lack in-country WHO-prequalified laboratory capacity + supports EAC-MRH regional pharmacovigilance.
• Counterfeit-medicine forensics — NQCL conducts forensic chemical analysis on suspect counterfeit medicines + supports PPB + Anti-Counterfeit Authority + DCI (Directorate of Criminal Investigations) enforcement.
• Capacity-building role — NQCL hosts training programmes for African pharmaceutical analysts + contributes to WHO + AUDA-NEPAD regulatory-strengthening initiatives.

PPB medical-device + IVD regulation operates under the PPB Medical Devices and IVDs Guidelines with a Class A-D risk-based framework substantively aligned with GHTF/IMDRF + EU MDR. Foreign manufacturers must appoint a Kenyan Authorised Representative (KAR).

• Risk-based Classification (Class A / B / C / D + IVD Class A-D) — substantively aligned with GHTF/IMDRF + EU MDR/IVDR with Kenyan-specific overlay.
• Registration Certificate — issued by PPB Directorate of Product Evaluation + Registration based on technical-file review + Kenyan Authorised Representative designation + English/Swahili labelling.
• Kenyan Authorised Representative (KAR) — Kenyan-resident legal entity required for foreign manufacturers; bears post-market materiovigilance responsibility + Kenyan regulatory interface.
• ISO 13485:2016 — recognised by PPB as QMS evidence framework; Kenyan-specific overlay required including Kenyan quality records + KAR QMS interface.
• Reliance pathways — PPB accepts CE Mark + FDA 510(k) + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence under reliance framework; reliance reduces dossier requirements + accelerates review.
• MDSAP — Kenya is not currently an MDSAP Participating Regulator + does not accept MDSAP audit reports as direct QMS evidence; ISO 13485 + Kenyan-specific overlay required.
• Post-market Materiovigilance — PPB operates medical-device adverse-event reporting through the Med Safety App + Yellow Form; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• Cosmetic Notification — cosmetics under PPB Cosmetics Guidelines require registration + Kenyan-specific labelling; INCI-aligned ingredient listing + safety substantiation + cosmetovigilance reporting.
• Kenyan UDI — PPB has not implemented full UDI equivalent to FDA UDI or EU EUDAMED UDI; Kenyan-specific labelling + product-identification requirements apply.
• Importation Permit — PPB Importation Permit required in addition to registration for foreign-manufactured devices entering Kenya.

PPB operates one of Africa's most active + best-developed pharmacovigilance systems through the National Pharmacovigilance Centre + the Med Safety App. Kenya was an early WHO Programme for International Drug Monitoring (PIDM) member + has contributed substantial ADR data to VigiBase via Uppsala Monitoring Centre.

• Med Safety App — PPB's mobile-app-based pharmacovigilance reporting tool launched 2017 (one of Africa's first + most-emulated mobile pharmacovigilance apps); available on iOS + Android in English + Swahili; substantially expanded ADR reporting volume + diversity (consumer + healthcare-professional reporting); model has been adopted by NAFDAC + Ghana FDA + TMDA + NDA + Rwanda FDA + Egyptian EDA + multiple other African + Asian regulators.
• Yellow Form — traditional paper-based ADR reporting form available in English + Swahili + distributed through healthcare facilities + pharmacies.
• National Pharmacovigilance Centre (NPC) — PPB Directorate of Pharmacovigilance, Clinical Trials + Cosmetovigilance operates the NPC + conducts ADR signal detection + risk-benefit analysis + risk communication.
• WHO PIDM Member — Kenya is a long-standing WHO Programme for International Drug Monitoring member + contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC).
• E2B(R3) ICSR — PPB accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); PPB-specific submission timeline + Kenyan-population focus.
• Active surveillance — PPB operates targeted active-surveillance programmes including for HIV antiretrovirals + malaria + tuberculosis medicines + COVID-19 vaccines.
• Cosmetovigilance — PPB operates one of Africa's most developed cosmetovigilance systems; Kenya has been a leader in addressing skin-lightening + mercury + hydroquinone cosmetic safety issues.

• WHO Maturity Level — PPB is pursuing WHO Maturity Level 3 (ML3) under the WHO Global Benchmarking Tool framework; ML3 ambition for vaccines + medicines as near-term milestone.
• WHO PQ Collaborative Registration Procedure (CRP) — active WHO PQ CRP Recipient with substantial use of CRP for vaccines + HIV + malaria + tuberculosis + reproductive-health medicines.
• WHO PQ Laboratory — NQCL is one of a handful of African WHO-prequalified pharmaceutical quality-control laboratories.
• WHO PIDM (Programme for International Drug Monitoring) — long-standing Kenya membership; substantial VigiBase ADR contribution.
• AUDA-NEPAD AMRH — leading participant in African Medicines Regulatory Harmonisation programme; co-leads EAC-MRH work-stream alongside TMDA + NDA + Rwanda FDA.
• EAC-MRH (East African Community Medicines Regulatory Harmonisation) — PPB is the leading EAC NRA + co-leads EAC-MRH Joint Assessment Procedure across 6 EAC Partner States (Kenya + Tanzania + Uganda + Rwanda + Burundi + South Sudan; + DR Congo since 2022).
• African Medicines Agency (AMA) — AU continental medicines agency under AMA Treaty (entered into force November 2021); Kenya is a leading AMA Member State + Kenya hosts senior AMA Secretariat positions.
• PIC/S Application — PPB has applied for PIC/S Membership; PPB GMP Guidelines + inspectorate practices substantively aligned with PIC/S GMP Guide + Annexes.
• ICDRA Member — active International Conference of Drug Regulatory Authorities participant; hosts ICDRA-related Africa-Region preparatory meetings.
• ICH Observer — PPB is an ICH Observer; ICH guidelines extensively referenced in Kenyan regulatory practice.
• Bilateral MoUs — PPB holds MoUs with FDA + EMA + MHRA + Health Canada + TGA + ANVISA + NMPA + MFDS + NAFDAC + Ghana FDA + SAHPRA + Egyptian EDA + TMDA + NDA + Rwanda FDA + Ugandan + Burundian + South Sudanese counterparts.
• Gavi / Global Fund / Gates Foundation / USAID cooperation — PPB works closely with Gavi (vaccine procurement), Global Fund (HIV/TB/malaria procurement), Gates Foundation (regulatory strengthening) + USAID (PEPFAR + maternal-child health programmes); NQCL serves as procurement QC lab.
• IMDRF Affiliate — PPB is an IMDRF Affiliate Member + draws on IMDRF guidance for medical-device regulation.

• Kenyan Authorised Representative or local Sponsor not properly designated — application rejected at PPB intake or post-approval compliance failure.
• Kenyan-specific labelling deficiencies — English + Swahili labelling + Kenyan-Shilling pricing-reference + Kenyan PIL + storage-condition Kenyan-climate appropriateness.
• GMP Guidelines gaps — applicants assuming EU GMP / PIC/S GMP compliance is sufficient without addressing Kenya-specific PPB GMP Guidelines + PPB-specific clarifications.
• Kenyan climate-zone stability data missing — Kenyan Climate Zone IVa/IVb (hot + dry to hot + humid; Mombasa coastal zone IVb) stability data required for medicines + biologicals; many EU-only + US-only stability packages insufficient.
• WHO PQ CRP eligibility not leveraged — WHO-PQ-approved products eligible for accelerated CRP review at PPB; missed opportunity for substantial review time + cost reduction.
• EAC-MRH joint assessment not leveraged — EAC-MRH joint assessment + reliance pathway underutilised by applicants targeting multiple East African Community markets.
• Pharmacy premises licensing scope misjudged — PPB regulates pharmacy premises licensing in addition to pharmaceutical products; sponsors with Kenyan distribution presence must account for premises-licensing obligations.
• Variations strategy not planned — Type IA / IB / II variations procedure substantively similar to WHO but with Kenya-specific timelines + fee structure.
• Renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Importation Permit not obtained — PPB Importation Permit required in addition to registration for foreign-manufactured medicines + devices entering Kenya.
• Port-of-entry inspection gaps — PPB Inspectorate inspection at Mombasa seaport + JKIA + Eldoret + Kisumu airports + land borders; importer logistics planning must account for inspection clearance time.
• Pharmacovigilance reporting gaps — PPB Pharmacovigilance + Med Safety App requirements substantively similar to WHO GVP + EU GVP but with Kenyan-specific format requirements + Kenyan-population pharmacovigilance focus + Swahili-language ICSR option.
• Cosmetovigilance scope not anticipated — PPB operates one of Africa's most developed cosmetovigilance systems; cosmetic sponsors must account for active cosmetovigilance obligations.
• Clinical trial NACOSTI gap — Kenyan clinical trials require PPB CTA + ERC + NACOSTI (National Commission for Science, Technology and Innovation) authorisation; sponsors sometimes overlook the NACOSTI step.
• Counterfeit-medicine framework underestimated — Anti-Counterfeit Act + PPB enforcement + Anti-Counterfeit Authority (ACA) + DCI cooperation; Kenyan Authorised Representative + Kenyan directors face personal liability for counterfeit-related findings.

V5 Ultimate provides the operational infrastructure Kenyan + foreign-supplier sites need for Pharmacy and Poisons Act Cap 244 + Health Act 21 of 2017 + PPB GMP Guidelines + PPB Drug Registration + PPB Medical Devices Guidelines + EAC-MRH + WHO PQ CRP + Med Safety App + NQCL readiness.

• PPB GMP Guidelines control framework — WHO TRS 986 Annex 2 + ICH Q7 + EU GMP-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Kenya-specific clarifications + Kenyan climate-zone IVa/IVb stability monitoring.
• PPB drug-registration packaging — Kenyan CTD-aligned dossier structure with Kenya Module 1 specifics + Module 3 stability + Kenyan PIL + English/Swahili labelling + Kenyan Authorised Representative declarations.
• WHO PQ CRP workflow — CRP Recipient packaging with WHO PQ Assessment Report + PPB-specific overlay + reduced dossier + accelerated 90-day review path.
• EAC-MRH workflow — EAC-MRH joint assessment + reliance pathway packaging for multi-country East African registration including Kenya + Tanzania + Uganda + Rwanda + Burundi + South Sudan + DRC.
• AMRH + AMA workflow — AU AMA + AUDA-NEPAD AMRH reliance pathway packaging for continental coverage.
• Kenyan Authorised Representative workflow — foreign-manufacturer KAR designation + role-management + Kenya-specific post-market surveillance + PPB interface.
• Kenyan clinical-trial workflow — PPB Good Clinical Practice + ERC + NACOSTI + KEMRI cooperation + Kenya-population pharmacovigilance + PPB CTA submission + Kenyan SUSAR reporting.
• PPB Pharmacovigilance + Med Safety App integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Swahili-language ICSR option + PPB NPC + Med Safety App + VigiBase upload.
• Cosmetovigilance workflow — PPB Cosmetovigilance Guidelines packaging + Kenyan cosmetic adverse-event reporting + Kenyan-specific cosmetic regulation including skin-lightening / mercury / hydroquinone safety controls.
• Medical-device + cosmetic + nutraceutical workflow — PPB Medical Devices Guidelines + Cosmetics Guidelines + Nutraceutical Guidelines dossier packaging + Class A-D + IVD classification + ISO 13485 + Kenyan Authorised Representative + post-market materiovigilance.
• Pharmacy premises licensing workflow — for sponsors with Kenyan distribution / pharmacy presence, V5 surfaces PPB pharmacy premises licensing + practice-standards requirements alongside product-registration workflows.
• PPB Variations workflow — Type IA / IB / II classification + PPB procedure + Kenyan packaging.
• Renewal workflow — 5-year renewal window tracking + PPB procedure packaging.
• EAC + AU regional bridging — for companies operating across East Africa + Africa, V5 surfaces PPB + TMDA + NDA + Rwanda FDA + Burundi DPML + South Sudan DFDA + DRC ACOREP + NAFDAC + Ghana FDA + South African SAHPRA + Egyptian EDA harmonised dossier-element reuse alongside national-specific extensions.